Treatment of Helicobacter pylori infection

被引:31
作者
Cavallaro, Lucas G.
Egan, Brian
O'Morain, Colm
Di Mario, Francesco
机构
[1] Univ Parma, Dept Clin Sci, Gastroenterol Sect, I-43100 Parma, Italy
[2] Univ Dublin Trinity Coll, Adelaide Meath Hosp, Dept Med, Dublin 24, Ireland
关键词
antimicrobial resistance; eradication; first-line treatment;
D O I
10.1111/j.1478-405X.2006.00428.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
In clinical practice the recommended treatment regimens achieve only an 80% Helicobacter pylori eradication rate and this rate is lower in patients who have failed first-line treatment. The increasing indications for H. pylori treatment (idiopathic thrombocytopenia and iron deficiency anemia) and an increasing trend of antibiotic resistance (especially in southern Europe) emphasize the need for more effective H. pylori eradication. Smoking and a short duration of treatment, especially in patients with functional dyspepsia, are predictors of eradication failure. In first line, the best option remains the clarithromycin-based regimens but an extended treatment duration is now indicated. Following first-line treatment failure, 14-day proton pump inhibitor triple therapy employing alternative antibiotics or quadruple therapy could be used. Levofloxacin-based 10-day triple therapy seems to be an encouraging strategy following one or more eradication failures.
引用
收藏
页码:36 / 39
页数:4
相关论文
共 37 条
[1]   7-day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity [J].
Antos, D ;
Schneider-Brachert, W ;
Bästlein, E ;
Hänel, C ;
Haferland, C ;
Buchner, M ;
Meier, E ;
Trump, F ;
Stolte, M ;
Lehn, N ;
Bayerdörffer, E .
HELICOBACTER, 2006, 11 (01) :39-45
[2]   Endemic iron deficiency associated with Helicobacter pylori infection among school-aged children in Alaska [J].
Baggett, HC ;
Parkinson, AJ ;
Muth, PT ;
Gold, BD ;
Gessner, BD .
PEDIATRICS, 2006, 117 (03) :E396-E404
[3]  
Boixeda D, 2003, REV ESP ENFERM DIG, V95, P206
[4]   Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection [J].
Borody, TJ ;
Pang, G ;
Wettstein, AR ;
Clancy, R ;
Herdman, K ;
Surace, R ;
Llorente, R ;
Ng, C .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 23 (04) :481-488
[5]   Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication:: A multicenter randomized trial [J].
Calvet, X ;
Ducons, J ;
Bujanda, L ;
Bory, F ;
Montserrat, A ;
Gisbert, JP .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (08) :1696-1701
[6]   Iron deficiency and Helicobacter pylori infection in the United States [J].
Cardenas, VM ;
Mulla, ZD ;
Ortiz, M ;
Graham, DY .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2006, 163 (02) :127-134
[7]   Rabeprazole containing triple therapy to eradicate Helicobacter pylori infection on the Texas-Mexican border [J].
Cardenas, VM ;
Graham, DY ;
El-Zimaity, HM ;
Opekun, AR ;
Campos, A ;
Chavez, A ;
Guerrero, L .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 23 (02) :295-301
[8]   Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection [J].
Cheon, JH ;
Kim, N ;
Lee, DH ;
Kim, JM ;
Kim, JS ;
Jung, HC ;
Song, IS .
HELICOBACTER, 2006, 11 (01) :46-51
[9]   Clarithromycin-resistant genotypes and eradication of Helicobacter pylori [J].
De Francesco, V ;
Margiotta, M ;
Zullo, A ;
Hassan, C ;
Trolani, L ;
Burattini, O ;
Stella, F ;
Di Leo, A ;
Russo, F ;
Marangi, S ;
Monno, R ;
Stoppino, V ;
Morini, S ;
Panella, C ;
Ierardi, E .
ANNALS OF INTERNAL MEDICINE, 2006, 144 (02) :94-100
[10]   Primary clarithromycin resistance in Italy assessed on Helicobacter pylori DNA sequences by TaqMan real-time polymerase chain reaction [J].
De Francesco, V ;
Margiotta, M ;
Zullo, A ;
Hassan, C ;
Valle, ND ;
Burattini, O ;
Cea, U ;
Stoppino, G ;
Amoruso, A ;
Stella, F ;
Morini, S ;
Panella, C ;
Ierardi, E .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 23 (03) :429-435